Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00372853 | Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma | completed | Phase 1 | 28 | AstraZenecaINDUSTRY | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00197860 | Dendritic Cell Based Therapy of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 40 | Inge Marie SvaneOTHER | 1 | Nov 23, 2011 | clinicaltrials |
| NCT00563147 |
| A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma |
| completed |
| Phase 1 |
| 28 |
| AVEO Pharmaceuticals, Inc.INDUSTRY |
| 1 |
| Oct 4, 2011 |
| clinicaltrials |
| NCT00113529 | Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 1 | Aug 29, 2011 | clinicaltrials |
| NCT01254838 | Novel Peptide Vaccination for Patients With Advanced Renal Cell Carcinoma | completed | Phase 1 | — | Iwate Medical UniversityOTHER | 0 | Dec 7, 2010 | clinicaltrials |
| NCT00422344 | A Study of RAD001 and Sunitinib in Metastatic Renal Cell Carcinoma | completed | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 26, 2010 | clinicaltrials |
| NCT00782587 | Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer(IPOP) | completed | Phase 1 | 14 | Halozyme TherapeuticsINDUSTRY | 1 | Feb 8, 2010 | clinicaltrials |
| NCT00351949 | IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | completed | Phase 1 | 24 | Immutep S.A.S.INDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00625768 | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | completed | Phase 1 | 13 | Antisoma ResearchINDUSTRY | 2 | Aug 25, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00095108 | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | completed | Phase 1 | 43 | ZymoGeneticsINDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00421512 | A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 11, 2008 | clinicaltrials |
| NCT00001383 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 52 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001683 | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00056173 | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Aptose Biosciences Inc.INDUSTRY | 1 | Jan 7, 2008 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2012source: clinicaltrials